Literature DB >> 25088037

CRIM1, the antagonist of BMPs, is a potential risk factor of cancer.

Hui Zeng, Liling Tang1.   

Abstract

Cysteine-rich motor neuron1 protein (CRIM1), a novel antagonist of bone morphogenetic proteins (BMPs), is reported to regulate the processing of BMPs preprotein into mature protein and the delivery of BMPs to the cell surface. Previous studies have shown that CRIM1 is an important player in regulating placental development, organogenesis, angiogenesis and kidney disease. Here, we propose that CRIM1 is a potential risk factor in cancer progression and metastasis. The epithelial-mesenchymal transition (EMT), which is characterized by the loss of epithelial phenotype and the acquisition of mesenchymal characteristics, is closely associated with invasion and metastasis of tumors. At the same time, it is hard for us to ignore the importance of angiogenesis in the genesis and progression of cancer. In this review we summarized the construction and previous researches of CRIM1. Furthermore, as it may be involved in tumor development and progression through its potential role in the EMT, capillary formation and angiogenesis maintenance, we proposed for the first time that CRIM1 may be a cancer related factor.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25088037     DOI: 10.2174/1568009614666140725094125

Source DB:  PubMed          Journal:  Curr Cancer Drug Targets        ISSN: 1568-0096            Impact factor:   3.428


  3 in total

1.  Low CRIM1 Levels Predict Poor Prognosis in Breast Cancer Patients.

Authors:  Wei Wen; Baohong Jiang; Xi Cao; Liming Xie; Xiaoli Zhang; Yuehua Li; Rongfang He
Journal:  Front Oncol       Date:  2022-05-06       Impact factor: 5.738

2.  Exploration of the mechanism of colorectal cancer metastasis using microarray analysis.

Authors:  Shuo Chen; Yan Wang; Lin Zhang; Yinan Su; Mingqing Zhang; Juan Wang; Xipeng Zhang
Journal:  Oncol Lett       Date:  2017-09-25       Impact factor: 2.967

3.  miR-665 Suppresses the Epithelial-Mesenchymal Transition and Progression of Gastric Cancer by Targeting CRIM1.

Authors:  Kun-Zhe Wu; Chun-Dong Zhang; Cheng Zhang; Jun-Peng Pei; Dong-Qiu Dai
Journal:  Cancer Manag Res       Date:  2020-05-15       Impact factor: 3.989

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.